Following several transformative milestones in psychedelics, coupled with a surge in biotech investment, 2024 is set to see a profound...
The European Medicines Agency (EMA) is set to hold a multi-stakeholder workshop on medical psychedelics in April 2024 to establish regulatory guidelines for the development and...
Beckley Psytech has confirmed it has received a strategic investment of USD$50 million from atai Life Sciences to accelerate the development of Beckley Psytech’s two clinical-stage,...
Psychedelics Today recently surveyed students and graduates of its 12-month intensive professional psychedelic certification programme, Vital, publishing its findings in The Emerging Psychedelic Workforce report.
Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges.
A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field.
Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by...
Biotech company Clearmind Medicine has announced receipt of a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq.
Global investment firm Psych Capital has announced the completion of its 100% acquisition of life science company Short Wave Pharma.
For the first time since Australia rescheduled MDMA and psilocybin, a shipment of the compounds has been made to the country to be used under the...